"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of ...

Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.

Lp (a) is a genetically driven variant of low-density lipoprotein (LDL) cholesterol, that is known to be an independent risk ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein (a) or Lp (a) levels in adults with high risk of cardiovascular events in a ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a ...

American Heart Association Scientific Sessions 2024, Abstract 4171286 - The oral medication muvalaplin may safely lower high ...